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Individuality in FGF1 expression significantly influences platinum
resistance and progression-free survival in ovarian cancer
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1Division of Cancer Research, Medical Research Institute, University of Dundee, Dundee, UK; 2Edinburgh Cancer Research Centre, MRC IGMM, University
of Edinburgh, Western General Hospital, Edinburgh EH2 2XR, UK; 3Tayside Cancer Centre, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK;
4CRUK Molecular Pharmacology Unit, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK
BACKGROUND: Ovarian cancer is frequently advanced at presentation when treatment is rarely curative. Response to first-line
platinum-based chemotherapy significantly influences survival, but clinical response is unpredictable and is frequently limited by the
development of drug-resistant disease.
METHODS: We used qRT–PCR analysis to assess intertumour differences in the expression of fibroblast growth factor 1 (FGF1) and
additional candidate genes in human ovarian tumours (n¼ 187), and correlated individuality in gene expression with tumour
histology, chemotherapy response and survival. We used MTT assays to assess platinum chemosensitivity in drug-sensitive and
drug-resistant ovarian cell lines.
RESULTS: Marked intertumour differences in gene expression were observed, with each tumour having a unique gene expression
profile. Nine genes, including FGF1 (P¼ 1.7 10 5) and FGFR2 (P¼ 0.003), were differentially expressed in serous and nonserous
tumours. MDM2 (P¼ 0.032) and ERBB2 (P¼ 0.064) expression was increased in platinum-sensitive patients, and FGF1 (adjusted log-
rank test P¼ 0.006), FGFR2 (P¼ 0.04) and PDRFRB expression (P¼ 0.037) significantly inversely influenced progression-free survival.
Stable FGF1 gene knockdown in platinum-resistant A2780DPP cells re-sensitised cells to both cisplatin and carboplatin.
CONCLUSION: We show for the first time that FGF1 is differentially expressed in high-grade serous ovarian tumours, and that
individuality in FGF1 expression significantly influences progression-free survival and response to platinum-based chemotherapy.
British Journal of Cancer (2012) 107, 1327–1336. doi:10.1038/bjc.2012.410 www.bjcancer.com
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Epithelial ovarian cancer, the second most common and most
lethal gynaecological malignancy, frequently presents at an
advanced stage where surgery is difficult and metastatic spread
common (http://www.isdscotlandarchive.scot.nhs.uk/isd/Cancer_
in_Scotland_summary.pdf). Treatment is therefore rarely curative,
with 5-year survival o10% in patients with stage IV disease
(Kristensen and Trope, 1997). Standard treatment combines
cytoreductive surgery and adjuvant or neoadjuvant chemotherapy
with platinum-taxane drug regimens (Scottish Intercollegiate
Guidelines Network, 2003), but prolonged response is frequently
compromised by the development of multidrug-resistant disease
(Clark et al, 2001).
Ovarian cancer (ICD-10 C56) describes several related diseases
with different cellular origins and molecular characteristics (Kobel
et al, 2008). The majority of high-grade serous cancers, the most
common and aggressive histological subtype, originate in the distal
fallopian tube (Lee et al, 2007) and show strong nuclear expression
of the Wilms’ tumour (WT-1) protein (Al-Hussaini et al, 2004).
Clear-cell cancers, in contrast, show similarities to renal cancers
(Zorn et al, 2005), whereas endometrioid cancers show similar
molecular abnormalities to endometriosis (Wiegand et al, 2010),
and mucinous ovarian cancers may represent metastases from
primary tumours in the gastrointestinal tract (Lee and Young,
2003). Despite the molecular diversity of the different histological
subtypes, ovarian cancer continues to be largely treated as a single
disease, in accordance with the national guidelines (Scottish
Intercollegiate Guidelines Network, 2003), and there are no
validated patient selection or chemotherapy response biomarkers
in routine clinical use.
Recent approaches to chemotherapy drug design have focussed
on inhibitors of angiogenesis, the process of new blood vessel
formation that promotes cancer progression, associated with
ovarian tumour growth, metastatic spread and ascites formation
(Brown et al, 2000). Angiogenesis inhibitors are primarily targeted
to growth factors (e.g., EGF, FGF, PDGF and VEGF) and associated
receptor tyrosine kinases (RTKs) that regulate key signal
transduction pathways frequently dysregulated in ovarian cancer
(Burger, 2011). VEGF ligands, for example, activate signalling
pathways including RAS/MAPK and PIK3CA/AKT to promote
angiogenesis; increased VEGFA expression has been associated
with ascites formation and poor prognosis (Prakash et al, 2010),
and phase III trials have recently demonstrated significantly
improved outcome in ovarian cancer patients receiving concomi-
tant and maintenance bevacizumab, a humanised monoclonal
antibody that inhibits VEGFA, in addition to standard first-line
chemotherapy (Burger et al, 2011; Perren et al, 2011).
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PDGF and associated receptors are also overexpressed in
ovarian tumours, where increased expression promotes angiogen-
esis, in part by increasing VEGF production (Dong et al, 2004).
Increased PDGFRA signalling is associated with more aggressive
tumour phenotypes (Henriksen et al, 1993) and with reduced
survival in ovarian cancer patients (Henriksen et al, 1993; Matei
et al, 2006), and fibroblast growth factor (FGF) expression is also
elevated in ovarian tumours (Fujimoto et al, 1997), in part because of
an FGF1 gene amplification associated with increased angiogenesis
and reduced patient survival (Birrer et al, 2007). Recent clinical trials
of PDGF- and FGF-targeted drugs in ovarian cancer have demon-
strated only modest survival benefits (Burger, 2011), possibly
because of lack of target specificity resulting from degeneracy of
growth factor signalling pathways or the development of drugs
designed to simultaneously target multiple RTK pathways to
maximise antiangiogenic effects (Ledermann and Raja, 2010;
Burger, 2011; Pliarchopoulou and Pectasides, 2011). Development
of patient selection or treatment response biomarkers is therefore
challenging, particularly when RTK-targeted drugs are prescribed
together with traditional cytotoxic chemotherapy.
Tumour-specific mutations are less common in ovarian cancer
than in other solid tumours (Kalamanathan et al, 2011) and,
therefore, unlike EGFR amplification to predict erlotinib sensitivity
(Lynch et al, 2004) and the association of KRAS mutation status
with cetuximab response (Garrett and Eng, 2011), they have limited
applicability as response biomarkers. There is therefore an urgent
clinical need to develop sensitive, quantitative assays to better
subclassify ovarian tumours, more logically select individual
patients most likely to respond to chemotherapy and to improve
clinical trial design. We have therefore developed quantitative real-
time PCR (qRT–PCR) methods to assess intertumour differences in
the expression of candidate genes including growth factors, RTK
drug targets, drug-metabolising enzymes and drug-resistance genes,
and have correlated individuality in gene expression with ovarian
tumour histology, chemotherapy response and patient survival.
MATERIALS AND METHODS
Demographics of ovarian cancer patient cohorts
Epithelial ovarian tumours of various histologies, obtained from
chemotherapy-naive patients, were provided by the Edinburgh
Experimental Cancer Medicine Centre (n¼ 96 fresh-frozen tumours,
patients diagnosed between January 1990 and April 2006) and
Tayside Tissue Bank (n¼ 91 formalin-fixed, paraffin-embedded
(FFPE) tumours, patients diagnosed between February 2005 and July
2009, Table 1, Supplementary Table S1). Tumour histology, FIGO
stage and grade were assessed by experienced pathologists, and
tumours subclassified as serous or nonserous (a combination of
mucinous, endometrioid and clear-cell histologies). Age at diagnosis,
the extent of surgical tumour debulking and chemotherapy response
information was obtained from individual patient case notes. All
patient recruitment was carried out following approval from the
Lothian Research Ethics Committee (08/S1101/41) or the Tayside
Tissue Bank Ethics Committee, a subcommittee of the Tayside
Committee on Medical Research Ethics. Written informed consent
was obtained from all study participants.
Tissue processing and RNA extraction
Fresh-frozen tissue Snap-frozen tumours (B20mg) were
suspended in lysis buffer (Qiagen, Crawley, UK) containing 1%
b-mercaptoethanol and disrupted using a rotor–stator homoge-
niser (Kinematica, Lucerne, Switzerland). RNA extraction was
performed using Qiagen RNeasy mini kits, according to the
manufacturer’s protocol for RNA extraction from animal tissues,
extended to include on column DNAse digestions (RNAse free
DNAse kit; Qiagen).
FFPE tissue Tumour-containing FFPE blocks were reviewed,
selected and histology confirmed by an experienced pathologist
(Professor CS Herrington). Three 20-mM sections were cut from each
block and combined for RNA extraction, using an Ambion Recoverall
Total Nucleic Acid Isolation Kit for FFPE tissues (Life Technologies,
Paisley, UK), according to the manufacturer’s instructions.
Analysis of RNA yield and Integrity
RNA yield and integrity was initially assessed from absorbance
readings at 260 and 280 nm using a Nanodrop 1000 spectro-
photometer (Thermo Fisher Scientific, Loughborough, UK). RNA
integrity was further confirmed in RNA extracted from fresh-
frozen tumours using an Agilent Bioanalyzer 2100 and RNA 6000
Nano LabChip Kit (Agilent Technologies, Edinburgh, UK),
according to the manufacturer’s guidelines. The Agilent Bioanlyser
calculates an RNA Integrity Number (RIN), ranging from 0
(completely degraded RNA) to 10 (fully intact RNA samples), and
represents RNA integrity as a size-sorted electropherogram. Both
RIN values (median 6.9, range 5.0–9.6) and electropherogram
traces were used to select RNA samples of sufficient quality for
gene expression analysis. RNA was initially extracted from 133
tumours – RNA from 13 tumours was of insufficient quality for
further analysis, and full clinical information was available for 96
of the remaining 120 tumours. It was not possible to similarly
assess RNA integrity in FFPE tumours (n¼ 91) using the Agilent
Bioanalyzer because of the more limited size range of RNA
fragments obtained from FFPE material.
cDNA preparation
RNA prepared from both fresh-frozen and FFPE tumours was
reverse transcribed into cDNA (50 ng RNA per 20 ml RT reaction)
Table 1 Patient demographics
Fresh FFPE
Age at diagnosis (years)
Median 63.5 63
Range 37–90 35–91
PFS (days)
Median 264.5 744
Range 0–6356 26–2202
Histology
Serous 59 65
Nonserous 37 26
FIGO stage
I 13 26
II 9 13
III 54 37
IV 17 5
Unknown 3 10
Grade of differentiation
Well 3 11
Moderately 13 10
Poorly 75 55
Unknown 5 15
Tumour debulking
Optimal debulking 41 2
Partial debulking 23 0
No debulking 23 80
Unknown 9 0
Abbreviations: FFPE¼ formalin-fixed, paraffin-embedded; FIGO¼ International
Federation of Gynaecology and Obstetrics; PFS¼ progression-free survival.
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using High Capacity RNA to cDNA kits (Applied Biosystems,
Warrington, UK), according to the manufacturer’s instructions.
qRT–PCR analysis
Fresh-frozen tissue cDNA prepared from RNA extracted from
fresh-frozen tumours was analysed on Format 32 384-well Taqman
Low Density Array (TLDA) cards (Applied Biosystems, Warrington,
UK), designed such that the expressions of 32 genes (31 target
genes and 18S ribosomal RNA as loading control, Supplementary
Table S2) were simultaneously analysed in triplicate; four tumour
samples were analysed on each card. Candidate genes for Taqman
analysis were identified from PubMed searches using combina-
tions of search terms including ovarian cancer, drug target,
angiogenesis, signalling pathway, chemotherapy, response, resis-
tance and platinum, inventoried Taqman probes identified
(Supplementary Table S3) and TLDA cards manufactured by
Applied Biosystems according to our specification.
PCR mixes were prepared by adding 10 ml of each cDNA sample
and 90 ml of sterile water to 100 ml of Taqman Universal PCR
Master Mix (Applied Biosystems), and added to the appropriate
TLDA sample ports. Following centrifugation (2 1min,
1200 r.p.m) to evenly distribute the reaction mixes, each card
was sealed (TLDA card sealer; Applied Biosystems) and run on a
Taqman 7900 real-time PCR system (Applied Biosystems) using
standard pre-defined thermal cycling conditions (50 1C for 2min,
94.5 1C for 10min, and then 40 cycles of 97 1C for 30 s and 59 1C
for 1min).
FFPE tissue Gene expression in FFPE tumours was analysed on
96-well plates, using individual Taqman assays optimised to work
on FFPE material (Taqman amplicons limited to 100 bp). Analysis
was restricted to genes (FGF1 and KIT) most significantly
associated with tumour histology in our fresh-frozen tumour
cohort, with the addition of WT-1 (Taqman probe ID
Hs01103749_m1), FGFR1 (Taqman probe ID Hs00915142_m1)
and FGFR2 (Taqman probe ID Hs01552926_m1). Analysis of KIT
expression was performed using the same Taqman assay used in
our TLDA card analysis (Supplementary Table S2); additional
‘short-amplicon’ Taqman assays were used for FGF1 (Taqman
probe ID Hs00265254_m1) and 18S ribosomal RNA (Taqman
probe ID Hs03003631_g1).
For single probe analysis, 20 ml individual reaction mixes (per
well) contained 10 ml Taqman Universal PCR Master Mix, 1 ml
gene-specific Taqman probe, 1 ml cDNA and 8 ml sterile water. Each
reaction was performed in triplicate and analysed on the Standard
Real Time PCR programme on a 7900 Taqman real-time PCR
system (Applied Biosystems), as described above.
Analysis of gene expression Analysis of both our single probe and
TLDA card experiments was performed using SDS 2.3 software
(Applied Biosystems). Optimal experimental baselines and thresh-
olds were chosen for each gene, and gene expression in individual
tumour samples quantitated by cycle threshold (Ct) values.
Relative expression values were determined by comparing the
expression of each target gene with the invariant ‘loading control’
18S ribosomal RNA, as previously described (Smith et al, 2003a,b).
All samples were analysed in triplicate and gene expression
calculated relative to 18S ribosomal RNA±compound error ((s.d.
target gene)2þ (s.d. 18S ribosomal RNA)2)½, where s.d. is the
standard deviation of the mean of triplicate replicates.
FGF1 gene copy number assay
To assess FGF1 copy number, DNA was extracted from our fresh-
frozen tumour cohort (n¼ 88) using an Ambion Recoverall Total
nucleic acid isolation kit from FFPE (Life Technologies) according
to the manufacturer’s instructions, and DNA concentration
determined using a Nanodrop 1000 spectrophotometer (Thermo
Scientific). Copy number was assessed using a quantitative
Taqman gene copy number assay (Taqman assay ID
Hs05994446_cn), where FGF1 copy number was compared with
the endogenous control gene RNAse P (copy number 2) by the
comparative Ct method, and relative quantitation values obtained
using CopyCaller Software (Applied Biosystems). As additional
controls, FGF1 and RNAse P copy numbers were assessed in
peripheral blood samples (n¼ 4), and copy numbers of 2
confirmed.
Correlation of gene expression with tumour histology,
chemotherapy response and patient survival
All statistical tests were performed using the PASW statistics
package version 18.0 (IBM, New York, USA). Kruskal–Wallis one-
way analysis of variance tests were performed to test for
differences in gene expression between different tumour histolo-
gies, in patients with platinum-sensitive and -resistant disease and
in platinum-sensitive and -resistant cell lines. Spearman’s rank
correlation analysis was used to investigate relationships between
the expression of individual genes, and the significance of the
Spearman’s co-efficient r2 assessed using Fisher’s transformation
tests. Log-rank analysis and Kaplan–Meier plots were performed to
correlate patient survival with gene expression, and the influence
of potential confounding factors including age at diagnosis,
tumour histology, tumour stage and grade and extent of surgical
tumour debulking evaluated using Cox regression analysis.
Immunohistochemical analysis of WT-1 expression
Sections (4 mM) from FFPE tumours were cut onto Superfrost plus
slides (VWR International Ltd, Lutterworth, UK) and dried for 1 h
at 60 1C before de-paraffinisation in Histoclear (Fisher Scientific)
and rehydration through a graded alcohol series. Sections were
microwaved for 10-min before immunostaining on a DAKO
autostainer (Dako, Ely, UK) using Vectastain ABC kits (Vector
Labs, Peterborough, UK) according to the manufacturer’s protocol.
Sections were blocked in horse serum containing 10% (v/v) avidin
solution (Vector Labs) for 20min followed by a 1-h incubation
with 1/50 dilution ofWT-1 primary antibody (clone 6F-H2; DAKO,
Ely, UK) including 10% (v/v) biotin solution (Vector Labs).
Sections were then incubated with biotinylated anti-mouse anti-
body for 30min followed by Vectastain Elite ABC reagent for
30min. Liquid diaminobenzidine (DAKO) was used as a chromo-
genic agent for 5min and sections counterstained with Mayer’s
haematoxylin. Sections known to stain positively were included in
each batch, and negative controls prepared by replacing the
primary antibody with TBS buffer.
Analysis of FGF1 expression in drug-sensitive and
drug-resistant ovarian cell lines
Paired drug-sensitive and drug-resistant cell lines were obtained
from Dr Simon Langdon, University of Edinburgh (PEO1/PEO4
and PEA1/PEA2; Langdon et al, 1988) or ATCC, LGC Standards,
Teddington, UK (A2780/A2780DPP; Lu et al, 1988). The PEO and
PEA series cell lines were derived from ascites fluid obtained from
ovarian cancer patients before and after the development of drug
resistance, whereas the drug-resistant A2780DPP cell line was
derived in vitro, following continuous selection in increasing
concentrations of cisplatin. PEO1 and PEO4 cells were maintained
in RPMI-1640 supplemented with 15% FBS, 0.1% glucose,
25mmol l 1 Hepes and 10mg l 1 insulin, PEA1, PEA2 and
A2780 cells in RPMI-1640 supplemented with 10% FBS, and
A2780DPP cells in RPMI-1640 supplemented with 15% FBS and
1 mM cisplatin in 37 1C incubators, supplemented with 5% CO2.
Cells were grown to 80% confluency in 75 cm2 flasks, harvested by
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trypsinisation, counted using a haemocytometer and 1 107 cells
used for RNA extraction using a Qiagen RNeasy mini kit (Qiagen),
following the manufacturer’s protocol for mammalian cells, with
on column DNAse digestion as described previously. The cDNA
was prepared as described previously and the expression of FGF1
and 18S ribosomal RNA assessed by qRT–PCR analysis.
Creation and characterisation of stable FGF1 knockdown
ovarian cell lines
FGF1 expression was stably knocked down in A780DPP cells by
RNA interference using Mission shRNA plasmids (Sigma-Aldrich,
Gillingham, UK). Five unique FGF1-specific shRNA plasmids
(clones A-TRC0000072524, B-TRC0000222594, C-TRC0000222593,
D-TRC0000072527 and E-TRC0000072525) and a negative control
plasmid were purchased as glycerol stocks and plasmid DNA
extracted using plasmid DNA maxi prep kits (Qiagen), according
to the manufacturer’s instructions. A2780DPP cells (2.5 105 cells
per well in 6-well plates) were transfected with each plasmid using
lipofectamine (Invitrogen, Paisley, UK), and shRNA-containing
cells selected with puromycin, according to the manufacturer’s
guidelines. Individual cell colonies were picked using cloning
cylinders, expanded to 75 cm2 tissue culture flasks and screened
for FGF1 expression by qRT–PCR analysis, as previously
described. FGF1 knockdown was confirmed using a quantitative
Human FGF acidic Quantikine Immunoassy (R&D Systems, Inc.,
Abingdon, UK) to compare FGF levels in cell supernatants
according to the manufacturer’s guidelines.
Ovarian cell line chemosensitivity assays
MTT assays (Mosmann, 1983) were used to compare the
chemosensitivity of A2780DPP and FGF1 knockdown cells to
cisplatin and carboplatin. Each cell line was plated in a 96-well
plate (5000 cells per well) and treated in triplicate with serial
dilutions of each drug, with drug concentrations selected to mimic
typical peak plasma levels in ovarian cancer patients (range
0–200% peak plasma; cisplatin 0.8–25 mM, carboplatin 2.7–85 mM).
Cells were treated for 72 h, media removed and 100 ml of a
0.5mgml 1 MTT solution (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide in phenol red free DMEM) added
and cells incubated at 37 1C for 3 h. The resulting formazan crystals
were solubilised in DMSO, quantitated spectrophotometrically at
570 nm and the percentage of live cells remaining following each
drug treatment calculated (assigning a value of 100% to vehicle-
treated cells). The IC50 values were calculated from log dose
response curves.
RESULTS
qRT–PCR analysis of individuality in gene expression
In initial experiments, we assessed intertumour variation in the
expression of 31 candidate genes including growth factors (FGF1,
FGF2, KITLG, VEGF), RTKs (CSF1R, KIT, EGFR, IGFR, FLT3,
ERBB, PDGFR, VEGFR), key nodes in signalling pathways
(PIK3CA, PTEN, AKT2, FRAP1, SRC, JUN) or mediators of
apoptosis (p53, MDM2, XIAP) and drug resistance (ABCB1,
ABCC2, GSTP1) (Supplementary Tables S2 and S3). qRT–PCR
analysis (format 32 TLDA cards) was used to compare gene
expression, relative to the loading control 18S ribosomal RNA, in
unselected fresh-frozen ovarian tumours (n¼ 96), as described in
Materials and Methods. Marked intertumour expression differ-
ences were observed (see, e.g., Figure 1A–D), with each tumour
having a unique expression profile. GSTP1 was the most
abundantly expressed gene in the majority of tumours, although
more than 70-fold variation in GSTP1 expression was observed
(Figure 1E). Similar intertumour variations in gene expression
were observed for all genes, and absolute gene expression varied
widely (Figure 1F and Supplementary Figure S1). Pair-wise
comparisons of gene expression revealed significant correlations
between the RTKs PDGFRA and PDGFRB (r2¼ 0.781, Po0.001),
VEGFR1 (FLT1) and VEGFR2 (KDR) (r2¼ 0.698, Po0.001) and
VEGFR2 and PRGFRB (r2¼ 0.716, Po0.001).
Correlation of gene expression with clinical parameters
Tumour histology To assess whether intertumour variation in
gene expression correlated with histology, we compared gene
expression in serous (n¼ 59) and nonserous (n¼ 37) tumours. To
validate tumour histology, we first compared WT-1 expression
(Figure 2A) and confirmed previous reports of increased expres-
sion in serous tumours (P¼ 0.001, P¼ 0.031 adjusted for multiple
testing). We identified an additional 6 genes (FGF1 (P¼ 1.7 10 5,
adjusted P¼ 5.27 10 4), ERBB4 (P¼ 0.004), JUN (P¼ 0.006),
VEGFB (P¼ 0.014), CSF1R (P¼ 0.03) and KDR (P¼ 0.079)) more
highly expressed in serous tumours and 3 genes (KIT (P¼ 0.005),
IGF2R (P¼ 0.04) and ABCC2 (P¼ 0.039)) more highly expressed in
nonserous tumours (Figure 2 and Supplementary Figure S2).
Patient survival
To assess whether gene expression influenced survival, progres-
sion-free survival intervals were calculated for all patients (days
between the end of the first course of chemotherapy and disease
progression or death) and compared with quartiles of gene
expression. FGF1 (adjusted log-rank test P¼ 0.006) and PDGFRB
(adjusted log-rank test P¼ 0.037) expression were significantly
inversely associated with survival in multivariate analysis
(Figure 3), where age, tumour histology, stage, grade and the
extent of tumour debulking were considered as possible con-
founders. Of these variables, only tumour stage was independently
associated with progression-free survival (P¼ 0.008). FGF1, but
not PDGFRB, expression was also significantly inversely associated
with overall patient survival (adjusted log-rank test P¼ 0.008,
Supplementary Figure S3).
As FGF1 gene amplification was previously associated with
survival (Birrer et al, 2007), we used quantitative Taqman gene
copy number assays to investigate whether individuality in FGF1
mRNA expression correlated with copy number variation. As
described in Materials and Methods, FGF1 copy number was
compared with endogenous control gene RNAse P (copy number 2),
and additionally with DNA from a reference blood sample with a
diploid genome. No FGF1 copy number changes were identified
(data not shown).
Correlation of gene expression with chemotherapy response
Response to first-line platinum-based chemotherapy, where
patients are defined as ‘sensitive’ if they relapse 46 months after
completion of treatment and ‘resistant’ if relapse occurs o6
months, is a significant determinant of subsequent chemosensi-
tivity and patient survival (Blackledge et al, 1989). To investigate
whether gene expression influenced chemosensitivity, we restricted
our analysis to a subgroup of 74 patients treated with either
single-agent cisplatin or carboplatin, or platinum and paclitaxel
drug combinations (additional patients had not received
chemotherapy or were not treated with platinum drugs;(Supple-
mentary Table S1A); therefore, our gene expression comparisons
in drug-sensitive and drug-resistant patients had limited power.
Interestingly, however, MDM2 (P¼ 0.032) and ERBB2 (P¼ 0.064)
expression was higher in platinum-sensitive patients, highlighting
associations that will be prioritised for future analysis in larger
patient cohorts.
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Validation of clinical associations
As these associations may help rationalise individuality in disease
progression and/or facilitate patient selection for targeted che-
motherapy, we extended our analysis to an additional cohort of
FFPE tumours to confirm our findings in archival material. As
described in Materials and Methods, we limited our PCR
amplicons to 100 bp, and performed pilot experiments to confirm
similar expression in matched fresh-frozen and FFPE tumours
(data not shown). We then investigated intertumour expression
differences in WT-1, FGF1 and KIT (genes that had previously
shown the most significant associations with tumour histology) in
FFPE tumours (n¼ 91). Again, marked intertumour differences in
gene expression and significant associations with tumour histology
were observed (Figure 4), where WT-1 (Po0.001, Figure 4A) and
FGF1 (P¼ 0.003, Figure 4C) were more highly expressed in serous
tumours and KIT (P¼ 0.013, Figure 4E) in nonserous tumours.
Increased WT-1 expression in serous tumours was confirmed by
immunohistochemistry using an antibody validated for routine
tumour histopathology (Figure 4B).
FGF1 activates signal transduction by binding to the RTKs
FGFR1 and FGFR2 (Turner and Grose, 2010). We therefore
additionally assessed individuality in FGF receptor expression in
both tumour cohorts, and again found marked intertumour
expression differences. Furthermore, there was a significant
correlation between FGF1 and FGFR2 (P¼ 0.026), but not FGFR1
(P¼ 0.214) expression and, similar to FGF1, FGFR2 was more
highly expressed in serous tumours (P¼ 0.003, Figure 4D). FGFR2
expression was also significantly inversely correlated with
progression-free survival in our fresh-frozen tumour cohort
(adjusted log-rank test P¼ 0.04), which was again independently
influenced by tumour stage (P¼ 0.05).
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Figure 1 TLDA cards were used to compare the expression of 31 candidate genes, relative to the expression of the loading control 18S ribosomal RNA,
as described in Materials and Methods. Gene expression was assessed in fresh-frozen ovarian tumours (n¼ 96), and is represented as mean±s.d. of
triplicate replicates. (A–D) Gene expression in 4 representative ovarian tumours; (E) intertumour variation in GSTP1 expression, where each bar represents
one tumour; (F) summary of variation in relative gene expression (box plot median) and the extent of intertumour variability in the expression of each gene
(box plot whiskers).
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FGF1 knockdown influences platinum chemosensitivity
To investigate whether FGF1 also influenced platinum resistance,
we used qRT–PCR analysis to compare FGF1 expression in paired
platinum-sensitive and -resistant ovarian tumour cell lines, and
found that FGF1 was consistently more highly expressed in
platinum-resistant cells (Figure 5A). As only the A2780/A2780DPP
cell line pair modelled single-agent platinum resistance (Lu et al, 1988),
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Figure 2 Association of gene expression with tumour histology. TLDA cards were used to compare gene expression in fresh-frozen ovarian tumours
(n¼ 96) as described in Materials and Methods, and tumours subclassified according to histology – serous tumours (n¼ 59) and nonserous tumours (n¼ 37,
combined mucinous, endometrioid and clear-cell histologies). WT-1 (A), FGF1 (B) and VEGFB (C) were significantly overexpressed in serous tumours; IGF2R
(D) and KIT (E) were significantly overexpressed in nonserous tumours. Significant differences in ABCC2, CSF1R, ERBB4, JUN and KDR gene expression were
also observed (Supplementary Data Figure S2).
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Figure 4 Validation of ovarian tumour histology associations. Single-gene Taqman probes were used to compare gene expression in FFPE ovarian
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Figure 5 FGF1 expression influences platinum chemosensitivity. qRT–PCR analysis was used to compare FGF1 expression in paired platinum-sensitive and
-resistant ovarian cancer cell lines, as described in Materials and Methods (A). FGF1 expression was stably knocked down in A2780DPP cells and reduction in
gene expression confirmed by qRT–PCR analysis (B) and quantitative immunoassay (C). MTT assays were used to compare chemosensitivity to (D)
cisplatin and (E) carboplatin in drug-sensitive A2780 cells, drug-resistant A2780DPP cells and A2780DPP/FGF1 knockdown cells, as described in Materials
and Methods.
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we stably knocked down FGF1 expression in A2780DPP cells.
As described in Materials and Methods, we isolated three
independent clones from each of five FGF1-specific shRNA
plasmids and compared FGF1 expression in all 15 cell lines by
qRT–PCR analysis (data not shown). The cell line derived from
clone A2 (A2780DPP/FGF1) resulted in the most significant FGF1
knockdown, as assessed by both qRT–PCR analysis (Figure 5B)
and immunoassay (Figure 5C), and was therefore used in
subsequent experiments.
MTT assays were used to compare platinum chemosensitivity in
A2780, A2780DPP and A2780DPP/FGF1 cells and significant
differences in sensitivity to both cisplatin (Figure 5D) and
carboplatin (Figure 5E) identified; A2780DPP cells were 17.6-fold
resistant to cisplatin and 3.7-fold cross-resistant to carboplatin.
FGF1 knockdown significantly re-sensitised A2780DPP cells to
cisplatin with a corresponding 84.4% decrease in IC50, and resulted
in a complete reversal of carboplatin resistance, where A2780DPP/
FGF1 cells had a significantly lower carboplatin IC50 (9.02 mM) than
both the platinum-sensitive A2780 (38.51 mM) and parental
platinum-resistant A2780DPP (141.98 mM) cell lines.
DISCUSSION
Our data describe marked intertumour differences in the
expression of several clinically relevant genes, and highlight novel
associations with tumour histology, chemotherapy response and
survival. Each tumour had a unique gene expression profile,
consistent with individuality in both disease progression
and treatment response, highlighting the potential for future
development of more personalised treatment approaches.
Our gene expression/tumour histology associations identify a
clinical variable that is routinely assessed but not routinely used
as a treatment selection biomarker. We showed significant
differences in the expression of several genes including FGF1
and KIT, which are targets for currently licenced chemotherapy
drugs or drugs in clinical trial, highlighting the potential utility
of tumour histology as a validated biomarker and important
co-variate in clinical trial design. We emphasise the importance of
extending our analysis to additional genes, and to clear-cell,
mucinous and endometrioid tumours – analysis of archival
FFPE material may facilitate tumour selection for future more
complex array-based experiments and multicentre collaborative
patient recruitment. Recently published whole genome micro-
array-based analyses from the Australian Ovarian Cancer Study
(AOCS; Tothill et al, 2008) illustrate both the power of
collaborative analysis and the necessity for comprehensive clinical
annotation, and have resulted in the identification of novel
molecular subtypes of both serous and endometrioid ovarian
cancers associated with poor prognosis (Tothill et al, 2008;
Konstantinopoulos et al, 2011).
Our data identify significant inverse relationships linking FGF1
expression with survival, highlighting functionally important
pathways that may influence tumour progression, and prioritising
targets for drug development. It was not possible to assess the
influence of individuality in gene expression on patient survival in
our FFPE tumour cohort, as the majority of patients had not
reached a 5-year census point post diagnosis. It is tempting to
speculate, however, that the striking similarities in gene expression
and our confirmation of highly significant histology associations in
fresh-frozen and FFPE tumours will, in time, also be replicated in
common survival associations. To support this hypothesis, we
investigated associations between FGF1 and PDGFRB expression
and both progression-free and overall survival in a published data
set (Affymetrix U133 Plus 2 arrays, Affymetrix, Santa Clara, CA,
USA) of 285 high-grade, advanced-stage serous ovarian, fallopian
tube and peritoneal tumours from the AOCS (Tothill et al, 2008).
In support of our findings, FGF1 expression was significantly
inversely associated with progression-free (time to relapse) and
overall (time to death) survival in each of three FGF1 probe sets
(adjusted Po0.001 and P¼ 0.030, respectively) and, in multi-
variate analysis, was influenced by tumour stage, but not by
tumour grade, histology or age at diagnosis. PDGFRB expression
was also significantly associated with survival in unadjusted data
from the AOCS data set (Po0.001), but the association was not
significant (P¼ 0.098) in multivariate analysis, where survival was
significantly influenced by tumour stage (P¼ 0.02).
Our analysis has not only quantitatively described intertumour
expression differences, but also delineated the relative importance
of highly homologous RTK pathway members. In particular,
FGF1 (but not FGF2) and FGFR2 (but not FGFR1) are differentially
expressed in serous and nonserous ovarian tumours. As FGFR2
expression also significantly influences survival, we hypothesise
that FGF1-dependent signalling in serous ovarian tumours
may be initiated by FGFR2 binding – we are currently testing
this hypothesis, and further evaluating the influence of FGF
signalling on cell proliferation and invasion. Consistent with
our findings, Cole et al (2010) have shown that FGFR2 knockdown
reduced cell proliferation and increased platinum chemosensitivity
in ovarian tumour cell lines and xenografts. As clinical practice
increasingly moves to the use of neoadjuvant chemotherapy,
we highlight the need to compare FGF1 and FGFR2 expression in
chemotherapy-naive, platinum-sensitive and platinum-resistant
ovarian cancer patients. Importantly, our findings that (1) FGF1
expression is increased in platinum-resistant ovarian tumour
cell lines, and (2) FGF1 knockdown re-sensitises ovarian cancer
cells to platinum drugs are entirely consistent with an inverse
association between FGF1 expression and survival in ovarian
cancer patients, and further supports the development of
FGF1-specific inhibitors. FGF1, together with VEGF and PDGF,
is a target for several pan-RTK drugs including cediranib (Astra
Zeneca, Alderley Park, UK), pazopanib (GlaxoSmithKline, Brent-
ford, UK) and BIBF 1120 (Boehringer Ingelheim, Bracknell, UK),
although no FGF1-specific agents are currently licenced. We
therefore highlight the need to further evaluate FGF1 and FGFR2 as
biomarkers of platinum sensitivity in larger independent patient
cohorts. Should our associations with platinum chemosensitivity
be confirmed, it will be of obvious interest to investigate whether
quantitative immunoassay-based assessment of serum FGF1 levels
may have clinical utility as a drug resistance biomarker.
Although our power to detect associations between gene
expression and chemotherapy response was limited, our data
suggest that MDM2 and ERBB2 expression may also influence
platinum sensitivity in chemotherapy-naive patients. In support of
these findings, MDM2 overexpression has been shown to sensitise
A2780 cells to cisplatin (Mi and Ni, 2003), whereas reduced MDM2
expression (inheritance of SNP309) was associated with increased
survival in ovarian cancer patients (Bartel et al, 2008). In contrast
to our data, however, clinical trials of the ERBB2 monoclonal
antibody inhibitor pertuzumab describe enhancement of carbo-
platin efficacy in ovarian tumours, and increased platinum
sensitivity in uterine (Cross et al, 2010) tumours overexpressing
ERBB2.
We have additionally described marked intertumour differences
in the expression of VEGFA, EGFR, IGFR, PIK3CA and SRC, targets
for newly licenced chemotherapy drugs (Banerjee and Kaye, 2011).
It will therefore be of interest in future studies to investigate
whether clinical response is influenced by individuality in gene
expression and/or by tumour histology. Individuality in GSTP1
expression has also previously been associated with platinum
sensitivity, and with the drug-resistance phenotype in ovarian
cancer cell lines and patients (Townsend and Tew, 2003; Peklak-
Scott et al, 2008); we are currently investigating whether, similar to
FGF1, GSTP1 directly influences platinum chemosensitivity. We
also found marked inter-tumour variability in expression of the
‘drug resistance’ genes ABCB1 (MDR1) and ABCC2 (MRP2),
Individuality in FGF1 signalling in ovarian cancer
G Smith et al
1334
British Journal of Cancer (2012) 107(8), 1327 – 1336 & 2012 Cancer Research UK
T
ra
n
sla
tio
n
a
l
T
h
e
ra
p
e
u
tic
s
previously associated with platinum (ABCB1 and ABCC2),
doxorubicin and vincristine (primarily ABCB1)-induced drug
resistance in ovarian cancer patients (Bourhis et al, 1989; Ohishi
et al, 2002). Although the development of drug resistance occurs as
an adaptive response to chemotherapy, our analysis of tumours
from chemotherapy-naive patients suggests that individual
tumours may, before treatment, have inherent differences in drug
sensitivity.
In summary, therefore, we describe marked individuality in the
expression of clinically relevant genes in ovarian tumours, and
highlight novel associations with tumour histology and survival,
consistent with individuality in disease progression and treatment
response. We show for the first time that FGF1 is differentially
expressed in aggressive high-grade serous ovarian tumours, and
that FGF1 expression is a significant determinant of survival and
response to platinum-based chemotherapy.
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